CA3087968A1 - Anti-siglec-7 antibodies having reduced effector function - Google Patents

Anti-siglec-7 antibodies having reduced effector function Download PDF

Info

Publication number
CA3087968A1
CA3087968A1 CA3087968A CA3087968A CA3087968A1 CA 3087968 A1 CA3087968 A1 CA 3087968A1 CA 3087968 A CA3087968 A CA 3087968A CA 3087968 A CA3087968 A CA 3087968A CA 3087968 A1 CA3087968 A1 CA 3087968A1
Authority
CA
Canada
Prior art keywords
antibody
siglec
region
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3087968A
Other languages
English (en)
French (fr)
Inventor
Christopher Bebbington
Wouter Korver
Nenad Tomasevic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allakos Inc
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of CA3087968A1 publication Critical patent/CA3087968A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3087968A 2018-01-11 2019-01-11 Anti-siglec-7 antibodies having reduced effector function Pending CA3087968A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616317P 2018-01-11 2018-01-11
US62/616,317 2018-01-11
PCT/US2019/013316 WO2019140273A1 (en) 2018-01-11 2019-01-11 Anti-siglec-7 antibodies having reduced effector function

Publications (1)

Publication Number Publication Date
CA3087968A1 true CA3087968A1 (en) 2019-07-18

Family

ID=67219179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3087968A Pending CA3087968A1 (en) 2018-01-11 2019-01-11 Anti-siglec-7 antibodies having reduced effector function

Country Status (6)

Country Link
US (1) US11912766B2 (https=)
EP (1) EP3737410A4 (https=)
JP (1) JP7342005B2 (https=)
AU (1) AU2019208025A1 (https=)
CA (1) CA3087968A1 (https=)
WO (1) WO2019140273A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
WO2023192992A2 (en) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology Bispecific natural killer engagers that target siglec-7
WO2023192993A2 (en) * 2022-03-31 2023-10-05 The Wistar Institute Of Anatomy And Biology Antibodies against human siglec-7 and use thereof for immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120815A2 (en) 2006-04-12 2007-10-25 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
CN101687924A (zh) * 2007-07-04 2010-03-31 株式会社未来创药研究所 抗Muc17抗体
PE20190658A1 (es) * 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
CA2896076C (en) * 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
MX383594B (es) * 2014-08-07 2025-03-14 Daiichi Sankyo Co Ltd Anticuerpo anti-orai1.
JP2017532025A (ja) * 2014-09-10 2017-11-02 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 交差反応性ｓｉｇｌｅｃ抗体
CA2996059A1 (en) 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
BR112018010172A2 (pt) * 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
WO2017123745A1 (en) 2016-01-12 2017-07-20 Palleon Pharma Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
WO2017153433A1 (en) * 2016-03-08 2017-09-14 Innate Pharma Siglec neutralizing antibodies
JP7137563B2 (ja) * 2016-08-05 2022-09-14 アラコス，インコーポレイティド がん治療用の抗Ｓｉｇｌｅｃ－７抗体

Also Published As

Publication number Publication date
WO2019140273A1 (en) 2019-07-18
US11912766B2 (en) 2024-02-27
US20210054072A1 (en) 2021-02-25
EP3737410A1 (en) 2020-11-18
EP3737410A4 (en) 2022-04-20
JP7342005B2 (ja) 2023-09-11
JP2021511298A (ja) 2021-05-06
AU2019208025A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
US11773162B2 (en) Anti-Siglec-7 antibodies for the treatment of cancer
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
TWI793325B (zh) 對cd3具特異性之抗體及其用途
US11912766B2 (en) Anti-Siglec-7 antibodies having reduced effector function
CA3100829A1 (en) Antibodies specific for gucy2c and uses thereof
IL293926A (en) Antibodies specific for cd47, pd-l1, and uses thereof
JP2017507953A (ja) 抗ｃｄ３８抗体との併用療法
CA2940865A1 (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
US20240209061A1 (en) Fusion proteins and uses thereof
WO2021139682A1 (en) Anti-galectin-9 antibody and uses thereof
US20250051464A1 (en) Epha2 antibodies
US20250042996A1 (en) Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
WO2019232323A1 (en) Bi-specific antibodies and use thereof
TW202523694A (zh) 抗muc16抗體及其用途
HK40033769A (en) Cd70 combination therapy
HK40046552B (zh) 对cd3特异性的抗体及其用途